Recent advances in the development of P2Y₁₄R inhibitors: a patent and literature review (2018-present)

REFERENCES

• Huang Z, Xie N, Illes P, et al. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021;6(1):162. doi: 10.1038/s41392-021-00553-z
   PubMed Web of Science ®Google Scholar
• Burnstock G. Introduction: P2 receptors. Curr Top Med Chem. 2004;4(8):793–803. doi: 10.2174/1568026043451014
   PubMed Web of Science ®Google Scholar
• Boeynaems J M, Robaye B, Janssens R, et al. Overview of P2Y receptors as therapeutic targets. Drug Dev Res. 2001;52(1–2):187–189. doi: 10.1002/ddr.1114
   Google Scholar
• Rafehi M, Müller C E. Tools and drugs for uracil nucleotide-activated P2Y receptors. Pharmacol Ther. 2018;190:24–80. doi: 10.1016/j.pharmthera.2018.04.002
   PubMedGoogle Scholar
• Scrivens M, Dickenson JM. Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression. Pharmacol Res. 2005;51(6):533–538. doi: 10.1016/j.phrs.2005.02.001
   PubMed Web of Science ®Google Scholar
• Ma J, Wei K, Liu J, et al. Glycogen metabolism regulates macrophage-mediated acute inflammatory responses. Nat Commun. 2020;11(1):1769. doi: 10.1038/s41467-020-15636-8
   PubMed Web of Science ®Google Scholar
• Das A, Ko H, Burianek L E, et al. Human P2Y 14 Receptor Agonists: Truncation of the Hexose Moiety of Uridine-5′-Diphosphoglucose and Its Replacement with Alkyl and Aryl Groups. J Med Chem. 2010;53(1):471–480. doi: 10.1021/jm901432g
   PubMed Web of Science ®Google Scholar
• Gauthier J Y, Belley M, Deschênes D, et al. The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14. Bioorg Med Chem Lett. 2011;21(10):2836–2839. doi: 10.1016/j.bmcl.2011.03.081
   PubMedGoogle Scholar
• Ko H, Fricks I, Ivanov A A, et al. Structure-activity relationship of uridine 5’-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem. 2007;50(9):2030–2039. doi: 10.1021/jm061222w
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang J, Gao Z-G, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509(7498):115–118. doi: 10.1038/nature13083
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang K, Gao Z-G, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014;509(7498):119–122. doi: 10.1038/nature13288
   PubMed Web of Science ®Google Scholar
• Kiselev E, Barrett M O, Katritch V, et al. Exploring a 2-Naphthoic Acid Template for the Structure-Based Design of P2Y14 Receptor Antagonist Molecular Probes. ACS Chem Biol. 2014;9(12):2833–2842. doi: 10.1021/cb500614p
   PubMed Web of Science ®Google Scholar
• Müller C E, Namasivayam V. Recommended tool compounds and drugs for blocking P2X and P2Y receptors. Purinergic Signal. 2021;17(4):633–648. doi: 10.1007/s11302-021-09813-7
   PubMedGoogle Scholar
• Robichaud J, Fournier J-F, Gagné S, et al. Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y14. Bioorg Med Chem Lett. 2011;21(14):4366–4368. doi: 10.1016/j.bmcl.2010.12.113
   PubMed Web of Science ®Google Scholar
• Barrett M O, Sesma J I, Ball C B, et al. A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose–Stimulated Chemotaxis of Human Neutrophils. Mol Pharmacol. 2013;84(1):41–49. doi: 10.1124/mol.113.085654 •• An excellent article reporting the structure of PPTN, useful for structure-based drug design.
   PubMedGoogle Scholar
• Charifson PS, Walters WP. Acidic and basic drugs in medicinal chemistry: a perspective. J Med Chem. 2014;57(23):9701–9717. doi: 10.1021/jm501000a
   PubMed Web of Science ®Google Scholar
• Mufti F, Jung Y-H, Giancotti L A, et al. P2Y 14 Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model. ACS Medicinal Chem Lett. 2020;11(6):1281–1286. doi: 10.1021/acsmedchemlett.0c00115
   PubMed Web of Science ®Google Scholar
• Salvemini D, Jacobson K A, inventors; Univ Saint Louis; Us Health, assignee. Treatment and Prevention of Neuropathic Pain with P2y14 Antagonists. Patent US2021024489A1; 2021.
   Google Scholar
• Jung Y-H, Yu J, Wen Z, et al. Exploration of alternative scaffolds for P2Y 14 receptor antagonists containing a biaryl core. J Med Chem. 2020;63(17):9563–9589. doi: 10.1021/acs.jmedchem.0c00745
   PubMed Web of Science ®Google Scholar
• Jacobson K a, Jung Y-H, Wen Z, inventors; Us Health; Jacobson Kenneth a; Jung Young Hwan; Wen Zhiwei, assignee. Heterocyclic P2y 14 Receptor Antagonists. Patent WO2022155037A1; 2022.
   Google Scholar
• Wen Z, Salmaso V, Jung Y-H, et al. Bridged Piperidine Analogues of a high affinity naphthalene-based P2Y 14 R antagonist. J Med Chem. 2022;65(4):3434–3459. doi: 10.1021/acs.jmedchem.1c01964
   PubMed Web of Science ®Google Scholar
• Breton S, inventor; Kantum Diagnostics Inc, assignee. Methods of Monitoring, Treating, and Preventing Renal Inflammation Associated with Infection. Patent WO2019212935A1; 2019.
   Google Scholar
• Wen Z, Pramanik A, Lewicki S A, et al. Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y 14 Receptor Antagonists. J Med Chem. 2023;66(13):9076–9094. doi: 10.1021/acs.jmedchem.3c00664 • An updated study on the P2YR inhibitor development.
   PubMed Web of Science ®Google Scholar
• Jung Y-H, Salmaso V, Wen Z, et al. Structure-Activity Relationship of Heterocyclic P2Y14 Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres. J Med Chem. 2021;64(8):5099–5122. doi: 10.1021/acs.jmedchem.1c00164
   PubMed Web of Science ®Google Scholar
• Yu J, Ciancetta A, Dudas S, et al. Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor. J Med Chem. 2018;61(11):4860–4882. doi: 10.1021/acs.jmedchem.8b00168 • An interesting article on P2Y,4 inhibitors.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hao K, Li H, et al. Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y14 receptor antagonists. Eur J Med Chem. 2019;181:111564. doi: 10.1016/j.ejmech.2019.111564
   PubMed Web of Science ®Google Scholar
• Jiang C, Hu Q, Zhang Z, et al. inventors; Univ China Pharma, assignee. 3-acylamino benzoic acid derivatives as well as preparation method and medical application thereof. Patent CN109096177A; 2018.
   Google Scholar
• Zhou M, Liu C, Guo Y, et al. HQL6 serves as a novel P2Y(14) receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis. Int Immunopharmacol. 2023;114:109507. doi: 10.1016/j.intimp.2022.109507
   PubMed Web of Science ®Google Scholar
• Lu R, Wang Y, Liu C, et al. Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y(14)R antagonists with potential high efficiency against acute gouty arthritis. Eur J Med Chem. 2021;216:113313. doi: 10.1016/j.ejmech.2021.113313
   PubMed Web of Science ®Google Scholar
• Faria J V, Vegi P F, Miguita A G C, et al. Recently reported biological activities of pyrazole compounds. Bioorg Med Chem. 2017;25(21):5891–5903. doi: 10.1016/j.bmc.2017.09.035
   PubMedGoogle Scholar
• Wang Y H, Zhou M Z, Ye T, et al. Discovery of a Series of 5-Amide-1H-pyrazole-3-carboxyl Derivatives as Potent P2Y(14)R Antagonists with Anti-Inflammatory Characters. J Med Chem. 2022;65(23):15967–15990. doi: 10.1021/acs.jmedchem.2c01632
   PubMedGoogle Scholar
• Jiang C, Hu Q, Lu R, et al. inventors; Univ China Pharma, assignee. 5-amino-1H-pyrazole derivative as well as preparation method and medical application thereof. Patent CN111423377A; 2020.
   Google Scholar
• Junker A, Balasubramanian R, Ciancetta A, et al. Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl derivatives as P2Y14 receptor antagonists. J Med Chem. 2016;59(13):6149–6168. doi: 10.1021/acs.jmedchem.6b00044
   PubMed Web of Science ®Google Scholar
• Lu R, Zhang Z, Jiang C. Recent progress on the discovery of P2Y(14) receptor antagonists. Eur J Med Chem. 2019;175:34–39. doi: 10.1016/j.ejmech.2019.04.068 • An interesting review on P2Y.R inhibitors.
   PubMed Web of Science ®Google Scholar
• Jacobson K a, Junker A, Uliassi E, et al. inventors; Us Health, assignee. Triazole Derivatives as P2y14 Receptor Antagonists. Patent WO2017053769 A1; 2017.
   Google Scholar
• Breton S, inventor; Kantum Diagnostics Inc, assignee. Methods of Monitoring, Treating, and Preventing Renal Inflammation Associated with Nephrotoxicity. Patent WO2019236777A1; 2019.
   Google Scholar
• Breton S, inventor; Kantum Diagnostics Inc, assignee. Methods of Monitoring Treating, and Preventing Renal Inflammation Following Cardiac Procedures or Events. Patent WO2019204289A1; 2019.
   Google Scholar
• Breton S, inventor; Kantum Diagnostics Inc, assignee. Methods of Monitoring, Treating, and Preventing Renal Inflammation Associated with Kidney Transplantation. Patent WO2019204283A1; 2019.
   Google Scholar
• Zificsak CA, Hlasta DJ. Current methods for the synthesis of 2-substituted azoles. Tetrahedron. 2004;60(41):8991–9016. doi: 10.1016/j.tet.2004.07.016
   Web of Science ®Google Scholar
• Davies J R, Kane P D, Moody C J. N-H insertion reactions of rhodium carbenoids. Part 5: A convenient route to 1,3-azoles. Tetrahedron. 2004;60(18):3967–3977. doi: 10.1016/j.tet.2004.03.037
   Web of Science ®Google Scholar
• Valente S, Tomassi S, Tempera G, et al. Novel reversible monoamine oxidase a inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. J Med Chem. 2011;54(23):8228–8232. doi: 10.1021/jm201011x
   PubMed Web of Science ®Google Scholar
• Chimenti F, Maccioni E, Secci D, et al. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-Methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. J Med Chem. 2008;51(16):4874–4880. doi: 10.1021/jm800132g
   PubMed Web of Science ®Google Scholar
• Chimenti F, Fioravanti R, Bolasco A, et al. Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors. J Med Chem. 2007;50(3):425–428. doi: 10.1021/jm060868l
   PubMed Web of Science ®Google Scholar
• La Regina G, Silvestri R, Artico M, et al. New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007;50(5):922–931. doi: 10.1021/jm060882y
   PubMed Web of Science ®Google Scholar
• Maccioni E, Alcaro S, Cirilli R, et al. 3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B. J Med Chem. 2011;54(18):6394–6398. doi: 10.1021/jm2002876
   PubMed Web of Science ®Google Scholar
• Chimenti F, Secci D, Bolasco A, et al. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N′-bis[2-oxo-2H-benzopyran]-3-carboxamides. Bioorg Med Chem Lett. 2006;16(15):4135–4140. doi: 10.1016/j.bmcl.2006.04.026
   PubMed Web of Science ®Google Scholar
• Liu Z Z, Zhao T Q, Li Z H, et al. Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors. Acta Pharmacol Sin B. 2020;10(8):1476–1491. doi: 10.1016/j.apsb.2019.12.008
   PubMedGoogle Scholar
• Fu D-J, Li P, Wu B-W, et al. Molecular diversity of trimethoxyphenyl-1,2,3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors. Eur J Med Chem. 2019;165:309–322. doi: 10.1016/j.ejmech.2019.01.033
   PubMed Web of Science ®Google Scholar
• Lu R, Zhang Z, Jiang C. Recent progress on the discovery of P2Y14 receptor antagonists. Eur J Med Chem. 2019;175:34–39. doi: 10.1016/j.ejmech.2019.04.068
   PubMed Web of Science ®Google Scholar
• Mufti F, Jung Y H, Giancotti L A, et al. P2Y(14) Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model. ACS Med Chem Lett. 2020;11(6):1281–1286. doi: 10.1021/acsmedchemlett.0c00115
   PubMed Web of Science ®Google Scholar
• Yu J, Ciancetta A, Dudas S, et al. Structure-Guided Modification of Heterocyclic Antagonists of the P2Y(14) Receptor. J Med Chem. 2018;61(11):4860–4882. doi: 10.1021/acs.jmedchem.8b00168
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu L, Zhang Y, et al. Discovery of novel MIF inhibitors that attenuate microglial inflammatory activation by structures-based virtual screening and in vitro bioassays. Acta Pharmacol Sin. 2022;43(6):1508–1520. doi: 10.1038/s41401-021-00753-x
   PubMed Web of Science ®Google Scholar
• Zhu J, Wu Y, Wang M, et al. Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors. Front pharmacol. 2020;11:566058. doi: 10.3389/fphar.2020.566058
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Zhou M, inventors; Univ China Pharma, assignee. Application of 2,2-(4-carboxyl octanamide group)methyl benzoate to preparation of drugs for treating inflammatory diseases. Patent CN109568304A; 2019.
   Google Scholar
• Wang W, Liu C, Li H, et al. Discovery of novel and potent P2Y14R antagonists via structure-based virtual screening for the treatment of acute gouty arthritis. J Adv Res. 2020;23:133–142. doi: 10.1016/j.jare.2020.02.007 .
   PubMed Web of Science ®Google Scholar
• Huang J, Zhou Z, Zhou M, et al. Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout. Bioorg Med Chem. 2018;26(8):1653–1664. doi: 10.1016/j.bmc.2018.02.013
   PubMed Web of Science ®Google Scholar
• Li H, Hu Q, Zhu Y, et al., inventors; Univ Soochow, assignee. Benzoxazole derivative as well as preparation method and application thereof. Patent CN114805236A; 2022.
   Google Scholar
• Zhou M, Wang W, Wang Z, et al. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y14R antagonists with anti-gout potential. Eur J Med Chem. 2022;227:113933. doi: 10.1016/j.ejmech.2021.113933 •• Another interesting article on P2Y,4 inhibitors.
   PubMed Web of Science ®Google Scholar
• Li H, Hu Q, Wang W, et al., inventors; Univ Suzhou, assignee. Benzoxazole derivative and preparation method and application thereof. Patent CN109574949A; 2019.
   Google Scholar
• Li H, Wang W, Hu Q, et al., inventors; Univ Suzhou, assignee. Benzoxazole derivative, and preparation method and application thereof. Patent CN110885318A; 2020.
   Google Scholar
• Hu Q, Li H, Liu C, inventors; Univ China Pharma, assignee. Benzofuran small-molecule P2Y receptor inhibitor and preparation and application thereof. Patent CN110776486A; 2020.
   Google Scholar
• Tian S, Wang, J M, Li, Y Y, et al. The application of drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev. 2015;86:2–10. doi: 10.1016/j.addr.2015.01.009
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803. doi: 10.1021/acs.jnatprod.9b01285
   PubMed Web of Science ®Google Scholar
• Atanasov, A G, Zotchev, S B, Dirsch, V M, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–216. doi: 10.1038/s41573-020-00114-z
   PubMed Web of Science ®Google Scholar
• Tian S, Wang J, Li Y, et al. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev. 2015;86:2–10. doi: 10.1016/j.addr.2015.01.009
   PubMed Web of Science ®Google Scholar
• Tian S, Li Y, Wang J, et al. Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines. J Cheminformatics. 2013;5(1):5. doi: 10.1186/1758-2946-5-5
   PubMed Web of Science ®Google Scholar
• Tian S, Wang J, Li Y, et al. Drug-likeness analysis of traditional Chinese medicines: prediction of drug-likeness using machine learning approaches. Mol Pharm. 2012;9(10):2875–2886. doi: 10.1021/mp300198d
   PubMed Web of Science ®Google Scholar
• Shen M, Tian S, Li Y, et al. Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines. J Cheminformatics. 2012;4(1):31. doi: 10.1186/1758-2946-4-31
   PubMedGoogle Scholar
• Liu C, Zhou M, Jiang W, et al. GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils. Front Immunol. 2022;13:870183. doi: 10.3389/fimmu.2022.870183
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Fang Y, et al., inventors; Univ China Pharma, assignee. Application of lobetyolin in preparation of medicine for treating diabetes. Patent CN113425734A; 2021.
   Google Scholar
• Yang T, Kong B, Gu J W, et al. Anticonvulsant and sedative effects of paederosidic acid isolated from Paederia scandens (Lour.) Merrill. in mice and rats. Pharmacol Biochem Behav. 2013;111:97–101. doi: 10.1016/j.pbb.2013.08.015
   PubMed Web of Science ®Google Scholar
• Yu P, Shi L, Song M, et al. Antitumor activity of paederosidic acid in human non-small cell lung cancer cells via inducing mitochondria-mediated apoptosis. Chem Biol Interact. 2017;269:33–40. doi: 10.1016/j.cbi.2017.02.003
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Zhu Y, et al. Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. Phytomedicine. 2023;115:154851. doi: 10.1016/j.phymed.2023.154851 •• An excellent article reporting the discovery of paederosidic acid.
   PubMed Web of Science ®Google Scholar
• Xu J, Morinaga H, Oh D, et al. GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity. J Immunol. 2012;189(4):1992–1999. doi: 10.4049/jimmunol.1103207
   PubMed Web of Science ®Google Scholar
• Harden T K, Sesma J I, Fricks I P, et al. Signalling and pharmacological properties of the P2Y receptor. Acta Physiol (Oxf). 2010;199(2):149–160. doi: 10.1111/j.1748-1716.2010.02116.x
   PubMedGoogle Scholar
• Rupp M, Bauer M R, Wilcken R, et al. Machine learning estimates of natural product conformational energies. PLoS Comput Biol. 2014;10(1):e1003400. doi: 10.1371/journal.pcbi.1003400
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi: 10.1038/s41586-021-03819-2
   PubMed Web of Science ®Google Scholar